Comparative Efficacy of Anti-tumor Necrosis Factor (TNF) Therapy in Inducing and Maintaining Remission from Crohn's Disease: A Systematic Review and Meta-analysis

Simple item page
dc.contributor.authorMirza, MSSen_US
dc.contributor.authorKhan, Men_US
dc.contributor.authorRahman, MSen_US
dc.contributor.authorNadeem, Aen_US
dc.contributor.authorAnugu, GRen_US
dc.contributor.authorMasmoum, MDen_US
dc.contributor.authorHameed, Zen_US
dc.contributor.authorKhawar, MHen_US
dc.contributor.authorMansoor, M.en_US
dc.date.accessioned2024-11-30T08:52:07Z
dc.date.available2024-11-30T08:52:07Z
dc.date.issued2024-08
dc.description.abstractBackground: Anti-TNF agents have emerged not only as inducers of remission but have also shown clinical efficacy in the maintenance of remission in patients suffering from Inflammatory Bowel Disease. However, there is limited quantitative evidence of their effectiveness in Crohn’s Disease. Aim: The current study aims to investigate the relative efficacy of anti-TNF agents in inducing and maintaining remission in Crohn’s Disease, by systematically evaluating efficacy outcomes, such as CDAI, SES-CD, and TEAEs. Methods: A number of digital databases were searched to retrieve relevant literature. This included PubMed, Google Scholar, Cochrane, ClinicalTrials.gov. The PICOS framework was used to systematically select the data. We used the PRISMA framework to synthesize and report the relevant data. Results: A total of 10 randomized control trials were included in the final sample. Among the anti-TNF agents, adalimumab and infliximab were most frequently used for disease control. Anti-TNF drugs were positively associated with clinical remission OR= 1.31 (95% CI (0.69, 2.10)), p<0.02; improved SES-CD scores (>50% reduction in endoscopic lesions), 1.65 (95% CI (1.44, 1.87)), p<0.0001; sustained CD remission significantly, -25.65 (95% CI (-33.22, -18.07)), p<0.001; and showed a relatively insignificant impact in lowering the incidence of treatment-emergent adverse effects 0.84 (95% CI (0.69, 1.03)), p=0.10. Conclusion: Infliximab and adalimumab should be taken into consideration as first-line alternatives for maintaining remission in Crohn's disease due to their better efficacy and set-up safety profiles.en_US
dc.identifier.affiliationsShandong University School of Medicine, Jinan, Chinaen_US
dc.identifier.affiliationsDow Medical College, Karachi, Pakistanen_US
dc.identifier.affiliationsTristar Horizon Medical Center, Dickson, Tennessee, USAen_US
dc.identifier.affiliationsOsmania Medical College, Hyderabad, Telangana, Indiaen_US
dc.identifier.affiliationsOsmania Medical College, Hyderabad, Telangana, Indiaen_US
dc.identifier.affiliationsAlfaisal University, Riyadh, Saudi Arabiaen_US
dc.identifier.affiliationsShifa College of Medicine, Islamabad, Pakistanen_US
dc.identifier.affiliationsKing Edward Medical University, Lahore, Pakistanen_US
dc.identifier.affiliationsAllama Iqbal Medical College, Lahore, Pakistan.en_US
dc.identifier.citationMirza MSS, Khan M, Rahman MS, Nadeem A, Anugu GR, Masmoum MD, Hameed Z, Khawar MH, Mansoor M.. Comparative Efficacy of Anti-tumor Necrosis Factor (TNF) Therapy in Inducing and Maintaining Remission from Crohn's Disease: A Systematic Review and Meta-analysis. Journal of Advances in Medicine and Medical Research. 2024 Aug; 36(9): 105-121en_US
dc.identifier.issn2456-8899
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/237253
dc.languageenen_US
dc.publisherMs. M. B. Mondalen_US
dc.relation.issuenumber9en_US
dc.relation.volume36en_US
dc.source.urihttps://doi.org/10.9734/jammr/2024/v36i95561en_US
dc.subjectAnti-tumor necrosis factoren_US
dc.subjectCrohn's disease activity indexen_US
dc.subjectCrohn's diseaseen_US
dc.titleComparative Efficacy of Anti-tumor Necrosis Factor (TNF) Therapy in Inducing and Maintaining Remission from Crohn's Disease: A Systematic Review and Meta-analysisen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
jammr2024v36n9p105.pdf
Size:
712.27 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Advances in Medicine and Medical Research